智通财经APP获悉，兆科眼科-B(06622)涨超5%，截至发稿，涨4.56%，报3.44港元，成交额170.7万港元。
消息面上，1月26日，兆科眼科-B发布公告，公司已扩大与领先健康护理产品制造商及分销商AFT Pharmaceuticals Limited(AFT)的伙伴协议，以于新加坡商业化BRIMOCHOL™ PF。公司亦已与亚洲领先眼科公司千寿制薬株式会社(千寿)建立策略伙伴关系，以于越南商业化该产品。
兆科分别授予AFT及千寿于新加坡及越南的独家分销权，当中包括于相关市场注册、进口、推广、分销、营销及销售BRIMOCHOL™ PF的权利。透过该等协议，AFT及千寿成为BRIMOCHOL™ PF的第七及第八名商业化伙伴，彰显公司进军全球的坚定承诺。
BRIMOCHOL™ PF乃一种用于矫正因老花眼而丧失近距离视力的潜在疗法，为公司经其伙伴Tenpoint Therapeutics,Ltd.(Tenpoint)授权取得的核心资产。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.